SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the publication of an abstract for a poster session at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The abstract relates to the results of the Phase 1 clinical trial of RXDX-105, the company’s orally available, small molecule multikinase inhibitor with potent activity against such targets as RET and BRAF. The poster session will be held on Sunday, June 5, 2016.
